← All trials
NCT06774261
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Jan 1, 2028
- First posted
- Jan 14, 2025
- Last posted
- Jan 14, 2025
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of StavangerLead sponsor
- Norwegian University of Science and TechnologyCollaborator
- University Hospital of North NorwayCollaborator
- National Institutes of Health (NIH)Collaborator
- University of ExeterCollaborator
- Helse FonnaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.